Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 338 followers
Latest posts
Last updated 26 minutes ago
Icon inks Anthropic partnership to deploy Claude into clinical trials
26 minutes ago
Contract research organization Icon announced a multi-year collaboration with Anthropic this week...
Smith & Nephew cuts 2026 outlook as US knee implant sales slide
31 minutes ago
Smith & Nephew has lowered its 2026 sales outlook after weakness in...
Amgen drops early-stage obesity drug, upping pressure on MariTide
about 1 hour ago
Amgen has ended development of its early-stage obesity drug AMG 513, foisting...
Lisata lays off 72% of staffers, sues Kuva after planned merger falls apart
about 6 hours ago
Lisata is laying off 72% of its workforce, including its chief medical...
Fiercest Women in Life Sciences 2026: Nominations open now
about 7 hours ago
Who should be a 2026 Fiercest Woman in Life Sciences? Nominations are...
Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout
about 7 hours ago
Pfizer has axed two clinical-stage obesity programs, dropping a GLP-1 receptor agonist...
KKR inks $5.7B deal to take medtech manufacturing giant Integer private
about 8 hours ago
Private equity giant KKR is expanding its healthcare portfolio with a deal...
Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx
about 9 hours ago
Latigo Biotherapeutics has fleshed out its plans for an IPO to finance...
Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact
about 9 hours ago
Pathos AI has agreed to pay $125 million for a bispecific antibody-drug...
Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials
about 10 hours ago
A phase 2 trial of Merck & Co.’s anti-TL1A monoclonal antibody has...
Curium strikes up to $8B deal for radiopharma rival Lantheus
1 day ago
Months after reports first linked Curium to a potential Lantheus takeover, the...
BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger
1 day ago
BlossomHill Therapeutics plans to raise $111.7 million to fund the clinical journey...